Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04QLL
|
|||
| Drug Name |
hESC-derived RPE (MA09-hRPE)
|
|||
| Indication | Dry age-related macular degeneration [ICD-11: 9B75; ICD-10: H35.31] | Phase 1/2 | [1], [2] | |
| Myopic macular degeneration [ICD-11: 9B75.Y] | Phase 1/2 | [3] | ||
| Stargardt disease [ICD-11: 9B70; ICD-10: H35.5] | Phase 1 | [4] | ||
| Company |
Ocata Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01344993) Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration | |||
| REF 2 | ClinicalTrials.gov (NCT01674829) A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD) | |||
| REF 3 | ClinicalTrials.gov (NCT02122159) Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration | |||
| REF 4 | ClinicalTrials.gov (NCT01625559) Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.